晚期卵巢癌患者减瘤手术联合或不联合腹腔热灌注化疗(OVHIPEC-1):随机对照3期试验最终生存分析
OVHIPEC-1试验最终分析显示,在初次减瘤不适合的III期上皮性卵巢癌患者中,间歇性减瘤手术联合腹腔热灌注化疗(HIPEC)较单纯手术改善无进展生存和总生存,中位随访约10年。
要点
- 手术+HIPEC组中位无进展生存14.3个月 vs 单纯手术组10.7个月(HR 0.63,95%CI 0.48-0.83,p=0.0008)。
- 手术+HIPEC组中位总生存44.9个月 vs 单纯手术组33.3个月(HR 0.70,95%CI 0.53-0.92,p=0.011)。
- 最终生存结果证实HIPEC在间歇性减瘤手术中的长期生存获益。
核心结论
- 更新后的生存结果证实,对于接受间歇性减瘤手术的原发性III期上皮性卵巢癌患者,HIPEC具有长期生存获益。
研究设计与样本
- 开放标签、随机对照3期试验,在荷兰和比利时的8个HIPEC中心招募原发性上皮性III期卵巢癌患者。
- 患者随机1:1分配至间歇性减瘤手术组(n=123)或手术+HIPEC组(n=122),HIPEC使用顺铂100 mg/m2。
- 主要终点为无进展生存,次要终点为总生存,在意向治疗人群中分析。
主要发现
- 手术组114例(93%)发生复发、进展或死亡,中位无进展生存10.7个月(95%CI 9.6-12.0);手术+HIPEC组109例(89%),中位14.3个月(95%CI 12.0-18.5);HR 0.63(95%CI 0.48-0.83),分层log-rank p=0.0008。
- 手术组108例(88%)死亡,中位总生存33.3个月(95%CI 29.0-39.1);手术+HIPEC组100例(82%),中位44.9个月(95%CI 38.6-55.1);HR 0.70(95%CI 0.53-0.92),分层log-rank p=0.011。
- 手术组中位随访10.1年(95%CI 8.4-12.9),手术+HIPEC组中位随访10.4年(95%CI 9.5-13.3)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The OVHIPEC-1 trial previously showed that the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery resulted in improved progression-free and overall survival compared with cytoreductive surgery alone at 4·7 years of follow-up in patients with stage III epithelial ovarian cancer who were ineligible for primary cytoreduction. We report the final survival outcomes after 10 years of follow-up. METHODS: In this open-label, randomised, controlled, phase 3 trial, patients with primary epithelial stage III ovarian cancer were recruited at eight HIPEC centres in the Netherlands and Belgium. Patients were eligible if they were aged 18-76 years, had not progressed during at least three cycles of neoadjuvant carboplatin plus paclitaxel, had a WHO performance status score of 0-2, normal blood counts, and adequate renal function. Patients were randomly assigned (1:1) to undergo interval cytoreductive surgery without HIPEC (surgery group) or with HIPEC (100 mg/m2 cisplatin; surgery-plus-HIPEC group). Randomisation was done centrally by minimisation with a masked web-based allocation procedure at the time of surgery when residual disease smaller than 10 mm diameter was anticipated, and was stratified by institution, previous suboptimal cytoreductive surgery, and number of abdominal regions involved. The primary endpoint was progression-free survival and a secondary endpoint was overall survival, analysed in the intention-to-treat population (ie, all randomly assigned patients). This study is registered with ClinicalTrials.gov, NCT00426257, and is closed. FINDINGS: Between April 1, 2007, and April 30, 2016, 245 patients were enrolled and followed up for a median of 10·1 years (95% CI 8·4-12·9) in the surgery group (n=123) and 10·4 years (95% CI 9·5-13·3) in the surgery-plus-HIPEC group (n=122). Recurrence, progression, or death occurred in 114 (93%) patients in the surgery group (median progression-free survival 10·7 months [95% CI 9·6-12·0]) and 109 (89%) patients in the surgery-plus-HIPEC group (14·3 months [12·0-18·5]; hazard ratio [HR] 0·63 [95% CI 0·48-0·83], stratified log-rank p=0·0008). Death occurred in 108 (88%) patients in the surgery group (median overall survival 33·3 months [95% CI 29·0-39·1]) and 100 (82%) patients in the surgery-plus-HIPEC group (44·9 months [95% CI 38·6-55·1]; HR 0·70 [95% CI 0·53-0·92], stratified log-rank p=0·011). INTERPRETATION: These updated survival results confirm the long-term survival benefit of HIPEC in patients with primary stage III epithelial ovarian cancer undergoing interval cytoreductive surgery. FUNDING: Dutch Cancer Foundation (KWF Kankerbestrijding).
引用
- Aronson SL, Lopez-Yurda M, Koole SN, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial. Lancet Oncol. 2023. PMID: 37708912. doi:10.1016/S1470-2045(23)00396-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。